Search PubMed⌕ Search

Biomedical subjects

S Maayani

Publications and source records attributed to S Maayani.

At least 91 records · Page 5Linked to original sources
PubMed1980

The effect of typical and atypical neuroleptics on binding of [3H]spiroperidol in calf caudate.

The effect of typical and atypical neuroleptics on the binding of [3H]spiroperidol to calf caudate membranes was studied. Saturable or specific binding was defined as the difference between binding in the absence and in the presence of 1 microM d-butaclamol. Scatchard analysis revealed nonhomogeneity of the saturable sites. Inhibition constants (Ki) and IC50 values for various typical and atypical neuroleptics and for two clinically inactive butyrophenones were determined. The Ki and IC50 values of typical neuroleptics paralleled their potencies in vivo. By contrast, the binding potencies of atypical neuroleptics did not correlate with their effects in vivo. For example, the clinically active drug clozapine has an IC50 value similar to the clinically inactive butyrophenone AHR-1900. U-25, 927, another clinically inactive butyrophenone that does not increase dopamine turnover is more potent in the binding assay than perlapine, a drug that increases dopamine turnover and elevates serum prolactin levels. The most striking discrepancy between binding and properties in vivo was found for the benzamide derivatives, sulpiride and metoclopramide. These clinically active agents, which increase dopamine turnover, have much higher Ki values than the clinically inactive butyrophenones. It is concluded that binding assays with [3H]spiroperidol in calf caudate cannot account for the antidopamine effects in vivo of atypical neuroleptics.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1979

Localisation of phencyclidine-induced changes in brain energy metabolism.

The abuse of phencyclidine [1(1-phencylohexyl)piperidine, PCP], commonly referred to as angel dust or hog, is rapidly reaching epidemic proportions. PCP users often appear violent and increases in PCP-implicated homicides and suicides have been reported. In animal studies PCP has been demonstrated in brain up to 48 h after administration, long after blood levels become undetectable. However, there is little further information on the distribution of PCP within the central nervous system with regard to the possible sites of action. Recently, Sokoloff and associates described a new technique which can be used to visualise possible sites of drug action. The technique is based on the premise that neuronal activity is closely related to energy metabolism. Therefore, by directly monitoring 2-deoxy-D-glucose consumption before and after a pharmacological stimulus, we can obtain autoradiographic evidence of changes in neuronal activity in discrete areas brain as a response to that stimulus. Using this procedure, we now report that PCP causes dramatic changes in glucose metabolism in very specific regions of the rat brain.

Animals↗
PubMed1979

Anticholinergic behavioral effect of phencyclidine.

Phencyclidine (PCP) impaired spatial alternation performance in rats. This effects was mimicked by antimuscarinic anticholinergics (scopolamine, atropine) and PCP derivatives (ketamine, cyclohexamine) but not by a variety of other agents. Muscarinic cholinergic agonists antagonized PCP. Impairment of spatial alteration performance by PCP appears to be mediated, at least in part, by and anticholinergic action; this is the first instance of a behavioral effect of PCP that can be largely attributed to a specific mechanism.

Animals↗
PubMed1979

Some structure activity relationships of phencyclidine derivatives as anticholinergic agents in vitro and in vivo.

Phencylidine derivatives exhibit multiple interactions with cholinergic systems: they block nicotinic and muscarinic receptors,and inhibit both acetyl and butyrylcholinesterase. In peripheral tissue, the net pharmacological effects of the phencyclidines is antiacetylcholine activity. The dissociation constants measured in isolated smooth muscle and from competition experiments for the muscarinic high-affinity binding sites in brain homogenates (Kd = 10(-5) - 10(-6) M) are 3--4 orders of magnitude lower than those of anticholinergic glycolate esters. However, phencyclidines have comparable potency to that of d-tubocurarine in blocking the nicotinic receptor in the isolated frog rectus abdominis (Kd = 10(-6) M). Brain uptake experiments of (3H) labeled phencyclidine showed that during the time period in which central effects are observed with these drugs their concentration in brain reaches values close to the Kd (10(-5) - 10(-6) M). This finding, and the cross tolerance observed in vivo between phencyclidine and other centrally acting cholinergic drugs supports the possible involvement of cholinergic interactions in the psychotropic action of phenyclidine derivatives. Quantum chemical calculations of the interaction pharmacophores of drugs in the phencyclidine series have indicated the molecular determinants for the interaction of these drugs with the muscarinic receptor. The calculations revealed that these drugs can match the reactivity characteristics of ACh and the semi-rigid muscarinic agonist 3-acetoxyquinuclidine, but their rigid molecular frame will be conductive to antagonistic rather than agonistic activity when the drug-receptor complex is formed. The identification of a "cholinergic interaction pharmacophore" for these drugs by quantum mechanical calculations made possible the suggestion of other active phencyclidine derivatives, e.g. p-NH2 and p-OH analogs which proved to be equipotent to phencyclidine. The inactivity of the p-NO2 derivative was also predicted on this basis and served as an additional confirmation of the theoretical criterion for activity; the difference between the activities of the ethynyl and cyano derivatives was explained by the modification of the cholinergic interaction pharmacophore. On the basis of these theoretical predictions, electrophysiological studies were carried out by the others and the results prompted the suggestion that "physostigmine is of potential value in the treatment of post-operative patients emerging from ketamine anesthesia and in the treatment of phencyclidine overdosed patients".

Animals↗
PubMed1978

On the interaction of drugs with the cholinergic nervous system. I. Tolerance to phencyclidine derivatives in mice: pharmacological characterization.

Phencyclidine [1(1-phenylcylohexyl) piperidine] and cyclohexamine [1(1-phenylcyclohexyl) ethylamine) were used as model psychotropic drugs to study the phenomenon of tolerance in mice. The behavioral effects of these drugs were measured by forced motor activity using the rotarod test. Tolerance develops progressively with chronic treatment at a rate and to a degree that are dose-dependent. The optimal conditions for tolerance induction are s.c. administration with 4-h intervals. The process of tolerance development is expressed in concomitant changes in five indices chosen for its quantification: ED50 values, duration, duration-dose dependency, critical falling time, and body weight. All these changes were found to be totally reversible, with no carry-over between two consecutive tolerance cycles. It was established that cyclohexamine is a better tolerance-inducer than phencylidine, although the nature of the tolerance developed for both drugs is qualitatively similar.

Animals↗
PubMed1978

On the interaction of drugs with the cholinergic nervous system. II. Cross-tolerance between phencyclidine derivatives and cholinergic drugs.

A symmetrical cross-tolerance was found between two phencyclidine derivatives--phencyclidine and cyclohexamine--and also between two cholinergic drugs--physostigmine and oxotremorine. On the other hand, mice rendered tolerant to the phencyclidine derivatives showed cross-tolerance to these cholinergic drugs, but no cross-tolerance was observed in the opposite direction. The applicability of such experiments to the elucidation of neurochemical interactions of centrally acting drugs is discussed.

Animals↗
PubMed1978

Defining the histamine H2-receptor in brain: the interaction with LSD.

Two aspects of the complexities of the mode of action of drugs are described. One is the criteria and pitfalls of defining the interaction with specific receptors. The other is the need to consider each of the pharmacological effects of a drug as a concatenation of receptor events, because it has become clear that each drug may have substantial affinity for many specific receptors. Illustrating these ideas is a characterization of the histamine receptor linked to adenylate cyclase in brain. The activities of a series of H2-antagonists and H2-agaonists were shown to be the same on the histamine receptor linked to adenylate cyclase as on known H2-receptors. The KB values of antagonists and ED50 values of agonists were not distinguishable among these receptors. Notably, at high concentrations, the H1-antagonists are also competitive antagonists of the H2-receptor. Cyproheptadine has especially high affinity for the H2-receptor. It is the most potent H2-antagonist yet reported. Other published results are reviewed to show the variety of receptors that cyproheptadine has affinity for. Its affinity for serotonin receptors led us to examine other serotonin antagonists. On this H2-receptor linked to adenylate cyclase in homogenates of guinea pig hippocampus and cortex, D-LSD and D-2-bromo-LSD (BrLSD) were shown to be competitive antagonists of histamine. L-LSD, mescaline and psilocin were inactive. Noting congurency in the molecular structyre of D-LSD and known H2-antagonists, we predicted a new H2-antagonist. This prediction is shown to be correct: the compound has similar affinity to the H2-receptor as has LSD. The affinities of D-LSD and BrLSD for the H2-receptor are compared with their affinities for other receptors. The pharmacology of D-LSD and BrLSD is reviewed. Evidence is assembled that BrLSD has considerable central effects.

Adenylyl Cyclases↗
PubMed1977

Anticholinesterase and antiacetylcholine activity of 1-phenylcyclohexylamine derivatives.

The antiacetylcholine and anticholinesterase potencies of four 1-phenylcyclohexylamine derivatives were estimated by measuring their antagonism to the contractile response of smooth and striated muscles and their inhibition of cholinesterase activity. In addition, their affinities towards the central muscarinic receptor from mouse brain homogenate were determined by competition experiments in vitro. Relative to atropine, these drugs exerted mild antimuscarinic activity in both isolated smooth muscle and in the competition experiments. On the other hand, they were found to exert antinicotinic potencies equal to that of d-tubocurarine in the striated muscle. The concentration of (3H)-phencyclidine taken up by mouse brain in vivo could be correlated with its dissociation constants from the central muscarinic binding sites, as well as with the Ki values for acetylcholinesterase inhibition, both determined in vitro. Since these drugs have a similar rigid spatial molecular structure, it is proposed that the variations in the potency of their cholinergic interactions stemmed mainly from the structural changes in the region of the 'cationic head'.

Acetylcholine↗